Skip to content

Veracyte VCYT Cash ratio

Cash ratio at other companies

Guardant Health logo
Guardant HealthGH
3.8×+0.2×
Natera, Inc. logo
Natera, Inc.NTRA
1.9×-0.7×
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
0.6×-0.5×
Revvity logo
RevvityRVTY
0.7×-1.1×
Labcorp Holdings logo
Labcorp HoldingsLH
0.4×+0.2×
Quest Diagnostics logo
Quest DiagnosticsDGX
0.2×0.0×

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$4.29B+10.7%

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0.0×
Current ratio9.3×+4.2×

Where this comes from

Calculated from Veracyte’s reported figures.

Based on the most recent quarter.

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Veracyte's cash ratio?
Veracyte (VCYT) reported cash ratio of 4.7× in Q1 2026.
How has Veracyte's cash ratio changed year-over-year?
Veracyte's cash ratio increased by 88.8% year-over-year, from 2.5× to 4.7×.
What is the long-term trend for Veracyte's cash ratio?
Over 5 years (2020 to 2025), Veracyte's cash ratio has grown at a -21.9% compound annual growth rate (CAGR), from 20.9× to 6.1×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.